Acute Infectious Diarrhea

New England Journal of Medicine

Volumn 350, Issue 1, 2004, Pages 38-47

  Thielman, Nathan M ^a   Guerrant, Richard L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BISMUTH SALICYLATE; CEFTRIAXONE; CIPROFLOXACIN; CODEINE; COTRIMOXAZOLE; DIIODOHYDROXYQUIN; DIPHENOXYLATE; DOXYCYCLINE; LEVOFLOXACIN; LOPERAMIDE; METRONIDAZOLE; NALIDIXIC ACID; NITAZOXANIDE; NORFLOXACIN; OPIATE DERIVATIVE; PAREGORIC; PAROMOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIDIARRHEAL AGENT;

ABDOMINAL CRAMP; ACUTE DIARRHEA; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DEPENDENCE; EVALUATION; FEVER; HUMAN; INTESTINE INFECTION; MALE; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; VOMITING; ACUTE DISEASE; ANIMAL; BACTERIAL INFECTION; BACTERIUM; COMMUNICABLE DISEASE; FLUID THERAPY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PARASITOLOGY; PRACTICE GUIDELINE; PROTOZOON; REVIEW; TRAVEL;

ACUTE DISEASE; ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; BACTERIA; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DIARRHEA; FLUID THERAPY; HUMANS; INTESTINAL DISEASES, PARASITIC; MALE; PRACTICE GUIDELINES; PROTOZOA; TRAVEL;

EID: 0346787909     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp031534     Document Type: Article

References (57)

1. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003;81:197-204.
2. Guerrant RL, Kosek M, Lima AA, Lorntz B, Guyatt HL. Updating the DALYs for diarrhoeal disease. Trends Parasitol 2002;18: 191-3. [Erratum, Trends Parasitol 2002;18: 281.]
3. Guerrant RL, Kosek M, Lima AA, Lorntz B, Guyatt HL. Updating the DALYs for diarrhoeal disease. Trends Parasitol 2002;18: 191-3. [Erratum, Trends Parasitol 2002;18: 281.]
4. Herikstad H, Yang S, Van Gilder TJ, et al. A population-based estimate of the burden of diarrhoeal illness in the United States: FoodNet, 1996-7. Epidemiol Infect 2002;129: 9-17.
5. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999;5:607-25.
6. Preliminary FoodNet data on the incidence of foodborne illnesses - selected sites, United States, 2002. MMWR Morb Mortal Wkly Rep 2003;52:340-3.
7. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331-51.
8. Norovirus activity-United States, 2002. MMWR Morb Mortal Wkly Rep 2003;52:41-5. [Erratum, MMWR Morb Mortal Wkly Rep 2003;52:113.]
9. Norovirus activity-United States, 2002. MMWR Morb Mortal Wkly Rep 2003;52:41-5. [Erratum, MMWR Morb Mortal Wkly Rep 2003;52:113.]
10. Choi SW, Park CH, Silva TM, Zaenker EI, Guerrant RJ. To culture of not to culture: fecal lactoferrin screening for inflammatory bacterial diarrhea. J Clin Microbiol 1996;34: 928-32.
11. Gill CJ, Lau J, Gorbach SL, Hamer DH. Diagnostic accuracy of stool assays for inflammatory bacterial gastroenteritis in developed and resource-poor countries. Clin Infect Dis 2003;37:365-75.
12. Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr. Amebiasis. N Engl J Med 2003; 348:1565-73.
13. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
14. Bauer TM, Lalvani A, Fehrenbach J, et al. Derivation and validation of guidelines for stool cultures for enteropathogenic bacteria other than Clostridium difficile in hospitalized adults. JAMA 2001;285:313-9.
15. Thielman NM, Guerrant RL. An algorithmic approach to the workup and management of HIV-related diarrhea. J Clin Outcomes Management 1997;4:36-47.
16. Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 1998;93:1300-5.
17. King CK, Glass R, Bresee JS, Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003;52(RR-16):1-16.
18. Food and Drug Administration. Antidiarrheal drug products for over-the-counter human use: final monograph: final rule. Fed Regist 2003;68(74):18869-82.
19. DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990;88:15S-19S.
20. Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992;165:557-60.
21. Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993;118:582-6.
22. DuPont HL, Hornick RB. Adverse effect oflomotil therapy in shigellosis. JAMA 1973; 226:1525-8.
23. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE. A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clin Neprhol 1994;42: 85-9.
24. Johnson PC, Ericsson CD, DuPont HL, Morgan DK, Bitsura JA, Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA 1986;255:757-60.
25. Fugueroa-Quintanilla D, Salazar-Lindo E, Sack RB, et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med 1993; 328:1653-8.
26. DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 1977;73:715-8.
27. Steinhoff MC, Douglas RG Jr, Greenberg HB, Callahan DR. Bismuth subsalicylate therapy of viral gastroentetitis. Gastroenterology 1980;78:1495-9.
28. Armon K, Stephenson T, MacFaul R, Eccleston P, Werneke U. An evidence and consensus based guideline for acute diarrhoea management. Arch Dis Child 2001;85:132-42.
29. Murphy MS. Guidelines for managing acute gastroenteritis based on a systematic review of published research. Arch Dis Child 1998;79:279-84.
30. Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized, placebo-controlled study. Ann Intern Med 1992;117: 202-8.
31. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992;117:297-302.
32. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157: H7 infections. N Engl J Med 2000;342:1930-6.
33. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000;181:664-70.
34. Tong MJ, Martin DG, Cunningham JJ, Gunning JJ. Clinical and bacteriological evaluation of antibiotic treatment in shigellosis. JAMA 1970;214:1841-4.
35. Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990;162:711-6.
36. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis. V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997;126:697-703.
37. Zimbabwe, Bangladesh, South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002;21:1136-41.
38. Salazar-Lindo E, Sack RB, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J Pediatr 1986;109:355-60.
39. Anders BJ, Lauer BA, Paisley JW, Reller LB. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982;1:131-2.
40. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999;340:1525-32.
41. Sanchez C, Garcia-Restoy E, Garau J, et al. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis 1993;168:1304-7.
42. Neill MA, Opal SM, Heelan J, et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991;114: 195-9.
43. Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157;H7 enteritis: a meta-analysis. JAMA 2002;288:996-1001.
44. Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996;22:1019-25.
45. Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990;150:541-6.
46. DuPont HL. Guidelines on acute infectious diarrhea in adults. Am J Gastroenterol 1997;92:1962-75.
47. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg Infect Dis 2002;8:1501-3.
48. Cheng AC, Thielman NM. Update on traveler's diarrhea. Curr Infect Dis Rep 2002; 4:70-7.
49. DuPont HL, Ericsson CD, Johnson PC, Bitsura JA, DuPont WW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 1987;257:1347-50.
50. Steffen R, DuPont HL, Heusser R, et al. Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob Agents Chemother 1986;29:625-7.
51. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998;351:256-61.
52. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:103-6.
53. Pape JW, Verdier RI, Boncy M, Boncy J, Johnson WD Jr. Cyclospora infection in adults infected with HIV: clinical manifestations, treatment, and prophylaxis. Ann Intern Med 1994;121:654-7.
54. Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients: a randomized, controlled trial. Ann Intern Med 2000;132:885-8.
55. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073-8.
56. Manatsathit S, Dupont HL, Farthing M, et al. Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol 2002;17:Suppl:S54-S71.
57. Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. The management of acute gastroenteritis in young children. Pediatrics 1996; 97:424-35.